相关实验视频

Updated: May 8, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

准线粒体RNA可以提高DNA脱甲基化剂的有效性

Stephanie Tan¹, Sujin Kim¹, Yoosik Kim^2,3,4,5

¹Department of Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Korea.

Scientific reports

|December 27, 2024

概括

向线粒体RNAs (mtRNAs) 可以提高化学疗法在肺癌中的有效性. 抑制mtRNA处理因子通过降低代谢活性和增加细胞死亡来提高低甲基化剂 (HMA) 的有效性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

低甲基化剂 (HMA) 如阿扎丁和迪西巴已被批准用于血液恶性瘤.
HMAs通过抑制DNA甲基转移酶,重新激活瘤抑制基因 (TSG) 和内源双链RNAs (dsRNAs) 来诱导病毒模拟的亡.
尽管诱导TSG和dsRNAs,但HMA在许多固体瘤中有效性有限.

研究的目的:

调查线粒体RNAs (mtRNAs) 在肺腺癌中HMA耐药性的作用.
确定新的治疗点,以提高HMA在固体瘤中的疗效.

主要方法:

对mtRNA处理因子的CRISPR查.
评估细胞死亡和代谢活动 (ATP产生) 作为对HMA治疗和mtRNA操纵的反应.
使用线粒体RNA聚合酶 (POLRMT) 的小分子抑制剂.

主要成果:

HMA治疗增加了mtRNA水平,增强了肺腺癌细胞中的代谢活性和ATP产生.
降低成熟mtRNA的表达或抑制POLRMT增加了HMA介导的细胞死亡.
通过抑制西诱导的ATP产生,使POLRMT和ELAC2对HMAs敏感的细胞耗尽.

结论:

升高的mtRNAs导致固体瘤中HMA不敏感.
针对mtRNA调节因子,如POLRMT,可以协同增强HMA的疗效.
mtRNA处理因子代表了改善HMA治疗结果的潜在治疗点.

关键词:

德西塔胺 (Decitabine) 的使用情况药物反应的药物反应低甲基化剂是一种低甲基化剂.线粒体RNA是什么?处理RNA处理RNA的过程

更多相关视频

Methodology for Accurate Detection of Mitochondrial DNA Methylation

Methodology for Accurate Detection of Mitochondrial DNA Methylation

Published on: May 20, 2018

Simultaneous Mapping and Quantitation of Ribonucleotides in Human Mitochondrial DNA

Simultaneous Mapping and Quantitation of Ribonucleotides in Human Mitochondrial DNA

Published on: November 14, 2017

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Phase II Reactions: Methylation Reactions

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...

Animal Mitochondrial Genetics

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...